<?xml version="1.0" encoding="UTF-8"?>
<document id="29670000">
	<sentence id="s1" text="Patients with non-AR driven metastases may, however, benefit from therapies targeting the tumor microenvironment.">
		<entity id="s1.e1" charOffset="18-20"
			type="GENE" text="AR" ontology_id="231"/>
		<entity id="s1.e2" charOffset="90-95"
			type="HP" text="tumor" ontology_id="HP_0002664"/>
		<pair id="s1.p1" e1="s1.e1"
		    e2="s1.e2" pgr="false"/>
	</sentence>
	<sentence id="s2" text="Therefore, the current study specifically investigated bone cell activity in clinical bone metastases in relation to tumor cell AR activity, in order to gain novel insight into biological heterogeneities of possible importance for patient stratification into bone-targeting therapies.">
		<entity id="s2.e1" charOffset="117-122"
			type="HP" text="tumor" ontology_id="HP_0002664"/>
		<entity id="s2.e2" charOffset="128-130"
			type="GENE" text="AR" ontology_id="231"/>
		<pair id="s2.p1" e1="s2.e1"
		    e2="s2.e2" pgr="false"/>
	</sentence>
	<sentence id="s3" text="Importantly, bone cell activity was inversely correlated to tumor cell AR activity (measured as AR, FOXA1, HOXB13, KLK2, KLK3, NKX3-1, STEAP2, and TMPRSS2 expression) and to patient serum prostate-specific antigen (PSA) levels.">
		<entity id="s3.e1" charOffset="60-65"
			type="HP" text="tumor" ontology_id="HP_0002664"/>
		<entity id="s3.e2" charOffset="71-73"
			type="GENE" text="AR" ontology_id="231"/>
		<entity id="s3.e3" charOffset="100-105"
			type="GENE" text="FOXA1" ontology_id="3169"/>
		<entity id="s3.e4" charOffset="115-119"
			type="GENE" text="KLK2" ontology_id="3817"/>
		<entity id="s3.e5" charOffset="127-133"
			type="GENE" text="NKX3-1" ontology_id="4824"/>
		<entity id="s3.e6" charOffset="135-141"
			type="GENE" text="STEAP2" ontology_id="261729"/>
		<entity id="s3.e7" charOffset="147-154"
			type="GENE" text="TMPRSS2" ontology_id="7113"/>
		<pair id="s3.p1" e1="s3.e1"
		    e2="s3.e2" pgr="false"/>
		<pair id="s3.p2" e1="s3.e1"
		    e2="s3.e3" pgr="false"/>
		<pair id="s3.p3" e1="s3.e1"
		    e2="s3.e4" pgr="false"/>
		<pair id="s3.p4" e1="s3.e1"
		    e2="s3.e5" pgr="false"/>
		<pair id="s3.p5" e1="s3.e1"
		    e2="s3.e6" pgr="false"/>
		<pair id="s3.p6" e1="s3.e1"
		    e2="s3.e7" pgr="false"/>
	</sentence>
	<sentence id="s4" text="Functional enrichment analysis indicated high bone morphogenetic protein (BMP) signaling in metastases with high bone cell activity and low tumor cell AR activity.">
		<entity id="s4.e1" charOffset="140-145"
			type="HP" text="tumor" ontology_id="HP_0002664"/>
		<entity id="s4.e2" charOffset="151-153"
			type="GENE" text="AR" ontology_id="231"/>
		<pair id="s4.p1" e1="s4.e1"
		    e2="s4.e2" pgr="false"/>
	</sentence>
	<sentence id="s5" text="This was confirmed by BMP4 immunoreactivity in tumor cells of metastases with ongoing bone formation, as determined by histological evaluation of van Gieson-stained sections.">
		<entity id="s5.e1" charOffset="22-26"
			type="GENE" text="BMP4" ontology_id="652"/>
		<entity id="s5.e2" charOffset="47-52"
			type="HP" text="tumor" ontology_id="HP_0002664"/>
		<pair id="s5.p1" e1="s5.e1"
		    e2="s5.e2" pgr="false"/>
	</sentence>
	<sentence id="s6" text="In conclusion, the inverse relation observed between bone cell activity and tumor cell AR activity in prostate cancer bone metastasis may be of importance for patient response to AR and/or bone targeting therapies, but needs to be evaluated in clinical settings in relation to serum markers for bone remodeling, radiography and patient response to therapy.">
		<entity id="s6.e1" charOffset="76-81"
			type="HP" text="tumor" ontology_id="HP_0002664"/>
		<entity id="s6.e2" charOffset="87-89"
			type="GENE" text="AR" ontology_id="231"/>
		<entity id="s6.e3" charOffset="111-117"
			type="HP" text="cancer" ontology_id="HP_0002664"/>
		<pair id="s6.p1" e1="s6.e1"
		    e2="s6.e2" pgr="false"/>
		<pair id="s6.p2" e1="s6.e2"
		    e2="s6.e3" pgr="false"/>
	</sentence>
</document>
